Cargando…

Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma †

Metastatic melanoma is a recalcitrant tumor. Although “targeted” and immune therapies have been highly touted, only relatively few patients have had durable responses. To overcome this problem, our laboratory has established the melanoma patient-derived orthotopic xenograft (PDOX) model with the use...

Descripción completa

Detalles Bibliográficos
Autor principal: Hoffman, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618524/
https://www.ncbi.nlm.nih.gov/pubmed/28858204
http://dx.doi.org/10.3390/ijms18091875
_version_ 1783267206367281152
author Hoffman, Robert M.
author_facet Hoffman, Robert M.
author_sort Hoffman, Robert M.
collection PubMed
description Metastatic melanoma is a recalcitrant tumor. Although “targeted” and immune therapies have been highly touted, only relatively few patients have had durable responses. To overcome this problem, our laboratory has established the melanoma patient-derived orthotopic xenograft (PDOX) model with the use of surgical orthotopic implantation (SOI). Promising results have been obtained with regard to identifying effective approved agents and experimental therapeutics, as well as combinations of the two using the melanoma PDOX model.
format Online
Article
Text
id pubmed-5618524
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-56185242017-09-30 Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma † Hoffman, Robert M. Int J Mol Sci Review Metastatic melanoma is a recalcitrant tumor. Although “targeted” and immune therapies have been highly touted, only relatively few patients have had durable responses. To overcome this problem, our laboratory has established the melanoma patient-derived orthotopic xenograft (PDOX) model with the use of surgical orthotopic implantation (SOI). Promising results have been obtained with regard to identifying effective approved agents and experimental therapeutics, as well as combinations of the two using the melanoma PDOX model. MDPI 2017-08-31 /pmc/articles/PMC5618524/ /pubmed/28858204 http://dx.doi.org/10.3390/ijms18091875 Text en © 2017 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hoffman, Robert M.
Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma †
title Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma †
title_full Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma †
title_fullStr Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma †
title_full_unstemmed Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma †
title_short Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma †
title_sort patient-derived orthotopic xenograft (pdox) models of melanoma †
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618524/
https://www.ncbi.nlm.nih.gov/pubmed/28858204
http://dx.doi.org/10.3390/ijms18091875
work_keys_str_mv AT hoffmanrobertm patientderivedorthotopicxenograftpdoxmodelsofmelanoma